NCT03965923View on ClinicalTrials.gov

Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy

PHASE3CompletedINTERVENTIONAL
Enrollment

1,104

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions
HIV Infections
Interventions
DRUG

Dapivirine (DPV) Vaginal Ring (VR)

Vaginal ring containing 25 mg of DPV

DRUG

Truvada Tablet

Tablet taken orally

Trial Locations (4)

2001

Wits RHI Shandukani Research Centre CRS, Johannesburg

Unknown

Blantyre CRS (Johns Hopkins Research Project/College of Medicine), Blantyre

MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala

Zengeza CRS, Chitungwiza

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03965923 - Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy | Biotech Hunter | Biotech Hunter